<VariationArchive VariationID="642539" VariationName="NM_000157.4(GBA1):c.222_224del (p.Thr75del)" VariationType="Deletion" Accession="VCV000642539" Version="23" RecordType="classified" NumberOfSubmissions="10" NumberOfSubmitters="10" DateLastUpdated="2024-06-23" DateCreated="2019-08-14" MostRecentSubmission="2024-02-14">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="626896" VariationID="642539">
      <GeneList>
        <Gene Symbol="GBA1" FullName="glucosylceramidase beta 1" GeneID="2629" HGNC_ID="HGNC:4177" Source="submitted" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>1q22</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="1" Accession="NC_000001.11" start="155234452" stop="155244627" display_start="155234452" display_stop="155244627" Strand="-" />
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="1" Accession="NW_003315906.1" start="39475" stop="49650" display_start="39475" display_stop="49650" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="1" Accession="NC_000001.10" start="155204238" stop="155214652" display_start="155204238" display_stop="155214652" Strand="-" />
          </Location>
          <OMIM>606463</OMIM>
        </Gene>
        <Gene Symbol="LOC106627981" FullName="GBA recombination region" GeneID="106627981" Source="calculated" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>1q22</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="1" Accession="NC_000001.11" start="155233639" stop="155240092" display_start="155233639" display_stop="155240092" Strand="+" />
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="1" Accession="NW_003315906.1" start="38662" stop="45115" display_start="38662" display_stop="45115" Strand="+" />
          </Location>
        </Gene>
      </GeneList>
      <Name>NM_000157.4(GBA1):c.222_224del (p.Thr75del)</Name>
      <CanonicalSPDI>NC_000001.11:155239968:GTA:</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>1q22</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="1" Accession="NC_000001.11" start="155239969" stop="155239971" display_start="155239969" display_stop="155239971" variantLength="3" positionVCF="155239968" referenceAlleleVCF="GGTA" alternateAlleleVCF="G" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="1" Accession="NC_000001.10" start="155209760" stop="155209762" display_start="155209760" display_stop="155209762" variantLength="3" positionVCF="155209759" referenceAlleleVCF="GGTA" alternateAlleleVCF="G" />
      </Location>
      <OtherNameList>
        <Name>p.Thr75del</Name>
      </OtherNameList>
      <ProteinChange>T75del</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000001.10" sequenceAccession="NC_000001" sequenceVersion="10" change="g.155209760_155209762del" Assembly="GRCh37">
            <Expression>NC_000001.10:g.155209760_155209762del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000001.11" sequenceAccession="NC_000001" sequenceVersion="11" change="g.155239969_155239971del" Assembly="GRCh38">
            <Expression>NC_000001.11:g.155239969_155239971del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_009783.1" sequenceAccession="NG_009783" sequenceVersion="1" change="g.9727_9729del">
            <Expression>NG_009783.1:g.9727_9729del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_042867.1" sequenceAccession="NG_042867" sequenceVersion="1" change="g.6431_6433del">
            <Expression>NG_042867.1:g.6431_6433del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000157.4" sequenceAccession="NM_000157" sequenceVersion="4" change="c.222_224del" MANESelect="true">
            <Expression>NM_000157.4:c.222_224del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000148.2" sequenceAccession="NP_000148" sequenceVersion="2" change="p.Thr75del">
            <Expression>NP_000148.2:p.Thr75del</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001822" Type="inframe_deletion" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001005741.3" sequenceAccession="NM_001005741" sequenceVersion="3" change="c.222_224del">
            <Expression>NM_001005741.3:c.222_224del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001005741.1" sequenceAccession="NP_001005741" sequenceVersion="1" change="p.Thr75del">
            <Expression>NP_001005741.1:p.Thr75del</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001822" Type="inframe_deletion" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001005742.3" sequenceAccession="NM_001005742" sequenceVersion="3" change="c.222_224del">
            <Expression>NM_001005742.3:c.222_224del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001005742.1" sequenceAccession="NP_001005742" sequenceVersion="1" change="p.Thr75del">
            <Expression>NP_001005742.1:p.Thr75del</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001822" Type="inframe_deletion" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001171811.2" sequenceAccession="NM_001171811" sequenceVersion="2" change="c.-40_-38del">
            <Expression>NM_001171811.2:c.-40_-38del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001623" Type="5 prime UTR variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001171812.2" sequenceAccession="NM_001171812" sequenceVersion="2" change="c.222_224del">
            <Expression>NM_001171812.2:c.222_224del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001165283.1" sequenceAccession="NP_001165283" sequenceVersion="1" change="p.Thr75del">
            <Expression>NP_001165283.1:p.Thr75del</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001822" Type="inframe_deletion" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001005741.2" sequenceAccession="NM_001005741" sequenceVersion="2" change="c.222_224del">
            <Expression>NM_001005741.2:c.222_224del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="761621516" DB="dbSNP" />
      </XRefList>
      <AlleleFrequencyList>
        <AlleleFrequency Value="0.00005" Source="The Genome Aggregation Database (gnomAD), exomes" />
        <AlleleFrequency Value="0.00007" Source="Exome Aggregation Consortium (ExAC)" />
        <AlleleFrequency Value="0.00016" Source="The Genome Aggregation Database (gnomAD)" />
        <AlleleFrequency Value="0.00019" Source="Trans-Omics for Precision Medicine (TOPMed)" />
      </AlleleFrequencyList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000157.4(GBA1):c.222_224del (p.Thr75del) AND not provided" Accession="RCV000796019" Version="11">
        <ClassifiedConditionList TraitSetID="9460">
          <ClassifiedCondition DB="MedGen" ID="C3661900">not provided</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2024-01-08" SubmissionCount="4">Pathogenic/Likely pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000157.4(GBA1):c.222_224del (p.Thr75del) AND multiple conditions" Accession="RCV001004136" Version="1">
        <ClassifiedConditionList TraitSetID="11607">
          <ClassifiedCondition DB="MedGen" ID="C1961835">Gaucher disease type I</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0268250">Gaucher disease type II</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0268251">Gaucher disease type III</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C1856476">Gaucher disease-ophthalmoplegia-cardiovascular calcification syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000157.4(GBA1):c.222_224del (p.Thr75del) AND Lewy body dementia" Accession="RCV002249507" Version="1">
        <ClassifiedConditionList TraitSetID="1938">
          <ClassifiedCondition DB="MedGen" ID="C0752347">Lewy body dementia</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2022-05-04" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000157.4(GBA1):c.222_224del (p.Thr75del) AND Gaucher disease" Accession="RCV001775006" Version="7">
        <ClassifiedConditionList TraitSetID="6268">
          <ClassifiedCondition DB="MedGen" ID="C0017205">Gaucher disease</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2023-01-16" SubmissionCount="3">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000157.4(GBA1):c.222_224del (p.Thr75del) AND multiple conditions" Accession="RCV002495045" Version="1">
        <ClassifiedConditionList TraitSetID="12838">
          <ClassifiedCondition DB="MedGen" ID="C1842704">Gaucher disease perinatal lethal</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C1961835">Gaucher disease type I</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0268250">Gaucher disease type II</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0268251">Gaucher disease type III</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C1856476">Gaucher disease-ophthalmoplegia-cardiovascular calcification syndrome</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0752347">Lewy body dementia</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C3160718">Parkinson disease, late-onset</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2022-04-12" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2024-01-08" NumberOfSubmissions="10" NumberOfSubmitters="10" DateCreated="2019-08-14" MostRecentSubmission="2024-02-14">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic/Likely pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">10796875</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">12587096</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">15352589</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">16293621</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">17059888</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">19394250</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">21704274</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">26792850</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">30169122</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">30548430</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">32035846</ID>
        </Citation>
        <DescriptionHistory Dated="2023-03-07">
          <Description>Pathogenic</Description>
        </DescriptionHistory>
        <ConditionList>
          <TraitSet ID="12838" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="2161" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">GAUCHER DISEASE, TYPE IIIC</ElementValue>
                <XRef Type="MIM" ID="231005" DB="OMIM" />
                <XRef Type="Allelic variant" ID="606463.0006" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gaucher disease type 3C</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Gaucher disease-ophthalmoplegia-cardiovascular calcification syndrome</ElementValue>
                <XRef ID="MONDO:0009268" DB="MONDO" />
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="12504" />
                <XRef ID="12504" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Gaucher disease (GD) encompasses a continuum of clinical findings from a perinatal lethal disorder to an asymptomatic type. The identification of three major clinical types (1, 2, and 3) and two other subtypes (perinatal-lethal and cardiovascular) is useful in determining prognosis and management. GD type 1 is characterized by the presence of clinical or radiographic evidence of bone disease (osteopenia, focal lytic or sclerotic lesions, and osteonecrosis), hepatosplenomegaly, anemia and thrombocytopenia, lung disease, and the absence of primary central nervous system disease. GD types 2 and 3 are characterized by the presence of primary neurologic disease; in the past, they were distinguished by age of onset and rate of disease progression, but these distinctions are not absolute. Disease with onset before age two years, limited psychomotor development, and a rapidly progressive course with death by age two to four years is classified as GD type 2. Individuals with GD type 3 may have onset before age two years, but often have a more slowly progressive course, with survival into the third or fourth decade. The perinatal-lethal form is associated with ichthyosiform or collodion skin abnormalities or with nonimmune hydrops fetalis. The cardiovascular form is characterized by calcification of the aortic and mitral valves, mild splenomegaly, corneal opacities, and supranuclear ophthalmoplegia. Cardiopulmonary complications have been described with all the clinical subtypes, although varying in frequency and severity.</Attribute>
                <XRef ID="NBK1269" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301446</ID>
                <ID Source="BookShelf">NBK1269</ID>
              </Citation>
              <XRef ID="2072" DB="Orphanet" />
              <XRef ID="C1856476" DB="MedGen" />
              <XRef ID="MONDO:0009268" DB="MONDO" />
              <XRef Type="MIM" ID="231005" DB="OMIM" />
            </Trait>
            <Trait ID="1362" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Gaucher disease type 1</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gaucher disease, noncerebral juvenile</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">GD 1</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Glucocerebrosidase deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Acid beta-glucosidase deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gaucher's disease, type 1</ElementValue>
                <XRef ID="Gaucher+Disease+Type+1/3002" DB="Genetic Alliance" />
                <XRef ID="62201009" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Gaucher disease type I</ElementValue>
                <XRef ID="MONDO:0009265" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">GBA DEFICIENCY</ElementValue>
                <XRef Type="MIM" ID="230800" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">GD I</ElementValue>
                <XRef Type="MIM" ID="230800" DB="OMIM" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">GD1</ElementValue>
                <XRef Type="MIM" ID="230800" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Gaucher disease (GD) encompasses a continuum of clinical findings from a perinatal lethal disorder to an asymptomatic type. The identification of three major clinical types (1, 2, and 3) and two other subtypes (perinatal-lethal and cardiovascular) is useful in determining prognosis and management. GD type 1 is characterized by the presence of clinical or radiographic evidence of bone disease (osteopenia, focal lytic or sclerotic lesions, and osteonecrosis), hepatosplenomegaly, anemia and thrombocytopenia, lung disease, and the absence of primary central nervous system disease. GD types 2 and 3 are characterized by the presence of primary neurologic disease; in the past, they were distinguished by age of onset and rate of disease progression, but these distinctions are not absolute. Disease with onset before age two years, limited psychomotor development, and a rapidly progressive course with death by age two to four years is classified as GD type 2. Individuals with GD type 3 may have onset before age two years, but often have a more slowly progressive course, with survival into the third or fourth decade. The perinatal-lethal form is associated with ichthyosiform or collodion skin abnormalities or with nonimmune hydrops fetalis. The cardiovascular form is characterized by calcification of the aortic and mitral valves, mild splenomegaly, corneal opacities, and supranuclear ophthalmoplegia. Cardiopulmonary complications have been described with all the clinical subtypes, although varying in frequency and severity.</Attribute>
                <XRef ID="NBK1269" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="2441" />
                <XRef ID="2441" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301446</ID>
                <ID Source="BookShelf">NBK1269</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2008">
                <ID Source="PubMed">18197057</ID>
                <ID Source="pmc">3110977</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACOG, 2009">
                <ID Source="PubMed">19888064</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Gaucher.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Decreased ß-glucocerebrosidase, Gaucher disease, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Gaucher-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Gaucher Disease; Decreased beta-glucocerebrosidase activity, 2022</CitationText>
              </Citation>
              <XRef ID="355" DB="Orphanet" />
              <XRef ID="77259" DB="Orphanet" />
              <XRef ID="C1961835" DB="MedGen" />
              <XRef ID="MONDO:0009265" DB="MONDO" />
              <XRef Type="MIM" ID="230800" DB="OMIM" />
            </Trait>
            <Trait ID="1363" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Acute neuronopathic Gaucher's disease</ElementValue>
                <XRef ID="Gaucher+Disease+Type+2/3003" DB="Genetic Alliance" />
                <XRef ID="12246008" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">GD 2</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gaucher disease, infantile cerebral</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gaucher disease, acute neuronopathic type</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Gaucher disease type II</ElementValue>
                <XRef ID="MONDO:0009266" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">GD II</ElementValue>
                <XRef Type="MIM" ID="230900" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gaucher disease type 2</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">GD2</ElementValue>
                <XRef Type="MIM" ID="230900" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Gaucher disease (GD) encompasses a continuum of clinical findings from a perinatal lethal disorder to an asymptomatic type. The identification of three major clinical types (1, 2, and 3) and two other subtypes (perinatal-lethal and cardiovascular) is useful in determining prognosis and management. GD type 1 is characterized by the presence of clinical or radiographic evidence of bone disease (osteopenia, focal lytic or sclerotic lesions, and osteonecrosis), hepatosplenomegaly, anemia and thrombocytopenia, lung disease, and the absence of primary central nervous system disease. GD types 2 and 3 are characterized by the presence of primary neurologic disease; in the past, they were distinguished by age of onset and rate of disease progression, but these distinctions are not absolute. Disease with onset before age two years, limited psychomotor development, and a rapidly progressive course with death by age two to four years is classified as GD type 2. Individuals with GD type 3 may have onset before age two years, but often have a more slowly progressive course, with survival into the third or fourth decade. The perinatal-lethal form is associated with ichthyosiform or collodion skin abnormalities or with nonimmune hydrops fetalis. The cardiovascular form is characterized by calcification of the aortic and mitral valves, mild splenomegaly, corneal opacities, and supranuclear ophthalmoplegia. Cardiopulmonary complications have been described with all the clinical subtypes, although varying in frequency and severity.</Attribute>
                <XRef ID="NBK1269" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="2442" />
                <XRef ID="2442" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301446</ID>
                <ID Source="BookShelf">NBK1269</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Gaucher.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Decreased ß-glucocerebrosidase, Gaucher disease, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Gaucher-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Gaucher Disease; Decreased beta-glucocerebrosidase activity, 2022</CitationText>
              </Citation>
              <XRef ID="77260" DB="Orphanet" />
              <XRef ID="C0268250" DB="MedGen" />
              <XRef ID="MONDO:0009266" DB="MONDO" />
              <XRef Type="MIM" ID="230900" DB="OMIM" />
            </Trait>
            <Trait ID="1364" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Subacute neuronopathic Gaucher's disease</ElementValue>
                <XRef ID="Gaucher+Disease+Type+3/3004" DB="Genetic Alliance" />
                <XRef ID="5963005" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">GD 3</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gaucher disease, juvenile and adult, cerebral</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gaucher disease, chronic neuronopathic type</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gaucher disease, subacute neuronopathic type</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gaucher Disease, Type 3</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Gaucher disease type III</ElementValue>
                <XRef ID="MONDO:0009267" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">GD III</ElementValue>
                <XRef Type="MIM" ID="231000" DB="OMIM" />
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="2443" />
                <XRef ID="2443" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Gaucher disease (GD) encompasses a continuum of clinical findings from a perinatal lethal disorder to an asymptomatic type. The identification of three major clinical types (1, 2, and 3) and two other subtypes (perinatal-lethal and cardiovascular) is useful in determining prognosis and management. GD type 1 is characterized by the presence of clinical or radiographic evidence of bone disease (osteopenia, focal lytic or sclerotic lesions, and osteonecrosis), hepatosplenomegaly, anemia and thrombocytopenia, lung disease, and the absence of primary central nervous system disease. GD types 2 and 3 are characterized by the presence of primary neurologic disease; in the past, they were distinguished by age of onset and rate of disease progression, but these distinctions are not absolute. Disease with onset before age two years, limited psychomotor development, and a rapidly progressive course with death by age two to four years is classified as GD type 2. Individuals with GD type 3 may have onset before age two years, but often have a more slowly progressive course, with survival into the third or fourth decade. The perinatal-lethal form is associated with ichthyosiform or collodion skin abnormalities or with nonimmune hydrops fetalis. The cardiovascular form is characterized by calcification of the aortic and mitral valves, mild splenomegaly, corneal opacities, and supranuclear ophthalmoplegia. Cardiopulmonary complications have been described with all the clinical subtypes, although varying in frequency and severity.</Attribute>
                <XRef ID="NBK1269" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301446</ID>
                <ID Source="BookShelf">NBK1269</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Gaucher.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Decreased ß-glucocerebrosidase, Gaucher disease, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Gaucher-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Gaucher Disease; Decreased beta-glucocerebrosidase activity, 2022</CitationText>
              </Citation>
              <XRef ID="355" DB="Orphanet" />
              <XRef ID="77261" DB="Orphanet" />
              <XRef ID="C0268251" DB="MedGen" />
              <XRef ID="MONDO:0009267" DB="MONDO" />
              <XRef Type="MIM" ID="231000" DB="OMIM" />
            </Trait>
            <Trait ID="3762" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Parkinson's disease</ElementValue>
                <XRef ID="Parkinson+Disease/5603" DB="Genetic Alliance" />
                <XRef ID="49049000" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Susceptibility to Parkinson's Disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">PARKINSON DISEASE, LATE-ONSET, SUSCEPTIBILITY TO</ElementValue>
                <XRef Type="Allelic variant" ID="606463.0048" DB="OMIM" />
                <XRef Type="Allelic variant" ID="157140.0021" DB="OMIM" />
                <XRef Type="Allelic variant" ID="606463.0008" DB="OMIM" />
                <XRef Type="Allelic variant" ID="606463.0001" DB="OMIM" />
                <XRef Type="Allelic variant" ID="601517.0001" DB="OMIM" />
                <XRef Type="Allelic variant" ID="603680.0001" DB="OMIM" />
                <XRef Type="Allelic variant" ID="600075.0001" DB="OMIM" />
                <XRef Type="Allelic variant" ID="607047.0001" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Parkinson disease, late-onset</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hereditary late onset Parkinson disease</ElementValue>
                <XRef ID="MONDO:0018466" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">PARK</ElementValue>
                <XRef Type="MIM" ID="168600" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Preferred">PD</ElementValue>
                <XRef Type="MIM" ID="168600" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="17684" />
                <XRef ID="17684" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301402</ID>
                <ID Source="BookShelf">NBK1223</ID>
              </Citation>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301446</ID>
                <ID Source="BookShelf">NBK1269</ID>
              </Citation>
              <Citation Type="general" Abbrev="EFNS, 2011">
                <ID Source="PubMed">20482602</ID>
              </Citation>
              <XRef ID="411602" DB="Orphanet" />
              <XRef ID="C3160718" DB="MedGen" />
              <XRef ID="MONDO:0008199" DB="MONDO" />
              <XRef Type="MIM" ID="168600" DB="OMIM" />
            </Trait>
            <Trait ID="1243" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Lewy body dementia</ElementValue>
                <XRef ID="Lewy+body+dementia/4215" DB="Genetic Alliance" />
                <XRef ID="MONDO:0007488" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Diffuse Lewy body disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Autosomal dominant diffuse Lewy body disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Lewy Body Disease</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">DLB</ElementValue>
                <XRef Type="MIM" ID="127750" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="3243" />
                <XRef ID="3243" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="practice guideline" Abbrev="NICE, 2023">
                <URL>https://www.nice.org.uk/guidance/cg148</URL>
                <CitationText>UK NICE Clinical guideline (CG148), Urinary incontinence in neurological disease: assessment and management, 2023</CitationText>
              </Citation>
              <XRef ID="C0752347" DB="MedGen" />
              <XRef ID="MONDO:0007488" DB="MONDO" />
              <XRef Type="MIM" ID="127750" DB="OMIM" />
            </Trait>
            <Trait ID="1913" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Gaucher disease perinatal lethal</ElementValue>
                <XRef ID="MONDO:0011945" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gaucher disease collodion type</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gaucher disease, perinatal-lethal form</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10675" />
                <XRef ID="10675" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Gaucher disease (GD) encompasses a continuum of clinical findings from a perinatal lethal disorder to an asymptomatic type. The identification of three major clinical types (1, 2, and 3) and two other subtypes (perinatal-lethal and cardiovascular) is useful in determining prognosis and management. GD type 1 is characterized by the presence of clinical or radiographic evidence of bone disease (osteopenia, focal lytic or sclerotic lesions, and osteonecrosis), hepatosplenomegaly, anemia and thrombocytopenia, lung disease, and the absence of primary central nervous system disease. GD types 2 and 3 are characterized by the presence of primary neurologic disease; in the past, they were distinguished by age of onset and rate of disease progression, but these distinctions are not absolute. Disease with onset before age two years, limited psychomotor development, and a rapidly progressive course with death by age two to four years is classified as GD type 2. Individuals with GD type 3 may have onset before age two years, but often have a more slowly progressive course, with survival into the third or fourth decade. The perinatal-lethal form is associated with ichthyosiform or collodion skin abnormalities or with nonimmune hydrops fetalis. The cardiovascular form is characterized by calcification of the aortic and mitral valves, mild splenomegaly, corneal opacities, and supranuclear ophthalmoplegia. Cardiopulmonary complications have been described with all the clinical subtypes, although varying in frequency and severity.</Attribute>
                <XRef ID="NBK1269" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301446</ID>
                <ID Source="BookShelf">NBK1269</ID>
              </Citation>
              <XRef ID="85212" DB="Orphanet" />
              <XRef ID="C1842704" DB="MedGen" />
              <XRef ID="MONDO:0011945" DB="MONDO" />
              <XRef Type="MIM" ID="608013" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="11607" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="2161" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">GAUCHER DISEASE, TYPE IIIC</ElementValue>
                <XRef Type="MIM" ID="231005" DB="OMIM" />
                <XRef Type="Allelic variant" ID="606463.0006" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gaucher disease type 3C</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Gaucher disease-ophthalmoplegia-cardiovascular calcification syndrome</ElementValue>
                <XRef ID="MONDO:0009268" DB="MONDO" />
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="12504" />
                <XRef ID="12504" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Gaucher disease (GD) encompasses a continuum of clinical findings from a perinatal lethal disorder to an asymptomatic type. The identification of three major clinical types (1, 2, and 3) and two other subtypes (perinatal-lethal and cardiovascular) is useful in determining prognosis and management. GD type 1 is characterized by the presence of clinical or radiographic evidence of bone disease (osteopenia, focal lytic or sclerotic lesions, and osteonecrosis), hepatosplenomegaly, anemia and thrombocytopenia, lung disease, and the absence of primary central nervous system disease. GD types 2 and 3 are characterized by the presence of primary neurologic disease; in the past, they were distinguished by age of onset and rate of disease progression, but these distinctions are not absolute. Disease with onset before age two years, limited psychomotor development, and a rapidly progressive course with death by age two to four years is classified as GD type 2. Individuals with GD type 3 may have onset before age two years, but often have a more slowly progressive course, with survival into the third or fourth decade. The perinatal-lethal form is associated with ichthyosiform or collodion skin abnormalities or with nonimmune hydrops fetalis. The cardiovascular form is characterized by calcification of the aortic and mitral valves, mild splenomegaly, corneal opacities, and supranuclear ophthalmoplegia. Cardiopulmonary complications have been described with all the clinical subtypes, although varying in frequency and severity.</Attribute>
                <XRef ID="NBK1269" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301446</ID>
                <ID Source="BookShelf">NBK1269</ID>
              </Citation>
              <XRef ID="2072" DB="Orphanet" />
              <XRef ID="C1856476" DB="MedGen" />
              <XRef ID="MONDO:0009268" DB="MONDO" />
              <XRef Type="MIM" ID="231005" DB="OMIM" />
            </Trait>
            <Trait ID="1362" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Gaucher disease type 1</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gaucher disease, noncerebral juvenile</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">GD 1</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Glucocerebrosidase deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Acid beta-glucosidase deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gaucher's disease, type 1</ElementValue>
                <XRef ID="Gaucher+Disease+Type+1/3002" DB="Genetic Alliance" />
                <XRef ID="62201009" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Gaucher disease type I</ElementValue>
                <XRef ID="MONDO:0009265" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">GBA DEFICIENCY</ElementValue>
                <XRef Type="MIM" ID="230800" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">GD I</ElementValue>
                <XRef Type="MIM" ID="230800" DB="OMIM" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">GD1</ElementValue>
                <XRef Type="MIM" ID="230800" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Gaucher disease (GD) encompasses a continuum of clinical findings from a perinatal lethal disorder to an asymptomatic type. The identification of three major clinical types (1, 2, and 3) and two other subtypes (perinatal-lethal and cardiovascular) is useful in determining prognosis and management. GD type 1 is characterized by the presence of clinical or radiographic evidence of bone disease (osteopenia, focal lytic or sclerotic lesions, and osteonecrosis), hepatosplenomegaly, anemia and thrombocytopenia, lung disease, and the absence of primary central nervous system disease. GD types 2 and 3 are characterized by the presence of primary neurologic disease; in the past, they were distinguished by age of onset and rate of disease progression, but these distinctions are not absolute. Disease with onset before age two years, limited psychomotor development, and a rapidly progressive course with death by age two to four years is classified as GD type 2. Individuals with GD type 3 may have onset before age two years, but often have a more slowly progressive course, with survival into the third or fourth decade. The perinatal-lethal form is associated with ichthyosiform or collodion skin abnormalities or with nonimmune hydrops fetalis. The cardiovascular form is characterized by calcification of the aortic and mitral valves, mild splenomegaly, corneal opacities, and supranuclear ophthalmoplegia. Cardiopulmonary complications have been described with all the clinical subtypes, although varying in frequency and severity.</Attribute>
                <XRef ID="NBK1269" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="2441" />
                <XRef ID="2441" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301446</ID>
                <ID Source="BookShelf">NBK1269</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2008">
                <ID Source="PubMed">18197057</ID>
                <ID Source="pmc">3110977</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACOG, 2009">
                <ID Source="PubMed">19888064</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Gaucher.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Decreased ß-glucocerebrosidase, Gaucher disease, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Gaucher-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Gaucher Disease; Decreased beta-glucocerebrosidase activity, 2022</CitationText>
              </Citation>
              <XRef ID="355" DB="Orphanet" />
              <XRef ID="77259" DB="Orphanet" />
              <XRef ID="C1961835" DB="MedGen" />
              <XRef ID="MONDO:0009265" DB="MONDO" />
              <XRef Type="MIM" ID="230800" DB="OMIM" />
            </Trait>
            <Trait ID="1363" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Acute neuronopathic Gaucher's disease</ElementValue>
                <XRef ID="Gaucher+Disease+Type+2/3003" DB="Genetic Alliance" />
                <XRef ID="12246008" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">GD 2</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gaucher disease, infantile cerebral</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gaucher disease, acute neuronopathic type</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Gaucher disease type II</ElementValue>
                <XRef ID="MONDO:0009266" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">GD II</ElementValue>
                <XRef Type="MIM" ID="230900" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gaucher disease type 2</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">GD2</ElementValue>
                <XRef Type="MIM" ID="230900" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Gaucher disease (GD) encompasses a continuum of clinical findings from a perinatal lethal disorder to an asymptomatic type. The identification of three major clinical types (1, 2, and 3) and two other subtypes (perinatal-lethal and cardiovascular) is useful in determining prognosis and management. GD type 1 is characterized by the presence of clinical or radiographic evidence of bone disease (osteopenia, focal lytic or sclerotic lesions, and osteonecrosis), hepatosplenomegaly, anemia and thrombocytopenia, lung disease, and the absence of primary central nervous system disease. GD types 2 and 3 are characterized by the presence of primary neurologic disease; in the past, they were distinguished by age of onset and rate of disease progression, but these distinctions are not absolute. Disease with onset before age two years, limited psychomotor development, and a rapidly progressive course with death by age two to four years is classified as GD type 2. Individuals with GD type 3 may have onset before age two years, but often have a more slowly progressive course, with survival into the third or fourth decade. The perinatal-lethal form is associated with ichthyosiform or collodion skin abnormalities or with nonimmune hydrops fetalis. The cardiovascular form is characterized by calcification of the aortic and mitral valves, mild splenomegaly, corneal opacities, and supranuclear ophthalmoplegia. Cardiopulmonary complications have been described with all the clinical subtypes, although varying in frequency and severity.</Attribute>
                <XRef ID="NBK1269" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="2442" />
                <XRef ID="2442" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301446</ID>
                <ID Source="BookShelf">NBK1269</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Gaucher.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Decreased ß-glucocerebrosidase, Gaucher disease, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Gaucher-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Gaucher Disease; Decreased beta-glucocerebrosidase activity, 2022</CitationText>
              </Citation>
              <XRef ID="77260" DB="Orphanet" />
              <XRef ID="C0268250" DB="MedGen" />
              <XRef ID="MONDO:0009266" DB="MONDO" />
              <XRef Type="MIM" ID="230900" DB="OMIM" />
            </Trait>
            <Trait ID="1364" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Subacute neuronopathic Gaucher's disease</ElementValue>
                <XRef ID="Gaucher+Disease+Type+3/3004" DB="Genetic Alliance" />
                <XRef ID="5963005" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">GD 3</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gaucher disease, juvenile and adult, cerebral</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gaucher disease, chronic neuronopathic type</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gaucher disease, subacute neuronopathic type</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gaucher Disease, Type 3</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Gaucher disease type III</ElementValue>
                <XRef ID="MONDO:0009267" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">GD III</ElementValue>
                <XRef Type="MIM" ID="231000" DB="OMIM" />
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="2443" />
                <XRef ID="2443" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Gaucher disease (GD) encompasses a continuum of clinical findings from a perinatal lethal disorder to an asymptomatic type. The identification of three major clinical types (1, 2, and 3) and two other subtypes (perinatal-lethal and cardiovascular) is useful in determining prognosis and management. GD type 1 is characterized by the presence of clinical or radiographic evidence of bone disease (osteopenia, focal lytic or sclerotic lesions, and osteonecrosis), hepatosplenomegaly, anemia and thrombocytopenia, lung disease, and the absence of primary central nervous system disease. GD types 2 and 3 are characterized by the presence of primary neurologic disease; in the past, they were distinguished by age of onset and rate of disease progression, but these distinctions are not absolute. Disease with onset before age two years, limited psychomotor development, and a rapidly progressive course with death by age two to four years is classified as GD type 2. Individuals with GD type 3 may have onset before age two years, but often have a more slowly progressive course, with survival into the third or fourth decade. The perinatal-lethal form is associated with ichthyosiform or collodion skin abnormalities or with nonimmune hydrops fetalis. The cardiovascular form is characterized by calcification of the aortic and mitral valves, mild splenomegaly, corneal opacities, and supranuclear ophthalmoplegia. Cardiopulmonary complications have been described with all the clinical subtypes, although varying in frequency and severity.</Attribute>
                <XRef ID="NBK1269" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301446</ID>
                <ID Source="BookShelf">NBK1269</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Gaucher.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Decreased ß-glucocerebrosidase, Gaucher disease, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Gaucher-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Gaucher Disease; Decreased beta-glucocerebrosidase activity, 2022</CitationText>
              </Citation>
              <XRef ID="355" DB="Orphanet" />
              <XRef ID="77261" DB="Orphanet" />
              <XRef ID="C0268251" DB="MedGen" />
              <XRef ID="MONDO:0009267" DB="MONDO" />
              <XRef Type="MIM" ID="231000" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="6268" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="14198" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Gaucher disease</ElementValue>
                <XRef ID="Gaucher+Disease/3000" DB="Genetic Alliance" />
                <XRef ID="MONDO:0018150" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Acute cerebral Gaucher disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Cerebroside lipidosis syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gaucher splenomegaly</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Sphingolipidosis 1</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Glucocerebrosidosis</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Glucosylceramidase deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Glucosyl cerebroside lipidosis</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Kerasin lipoidosis</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Kerasin thesaurismosis</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="8233" />
                <XRef ID="8233" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Gaucher disease (GD) encompasses a continuum of clinical findings from a perinatal lethal disorder to an asymptomatic type. The identification of three major clinical types (1, 2, and 3) and two other subtypes (perinatal-lethal and cardiovascular) is useful in determining prognosis and management. GD type 1 is characterized by the presence of clinical or radiographic evidence of bone disease (osteopenia, focal lytic or sclerotic lesions, and osteonecrosis), hepatosplenomegaly, anemia and thrombocytopenia, lung disease, and the absence of primary central nervous system disease. GD types 2 and 3 are characterized by the presence of primary neurologic disease; in the past, they were distinguished by age of onset and rate of disease progression, but these distinctions are not absolute. Disease with onset before age two years, limited psychomotor development, and a rapidly progressive course with death by age two to four years is classified as GD type 2. Individuals with GD type 3 may have onset before age two years, but often have a more slowly progressive course, with survival into the third or fourth decade. The perinatal-lethal form is associated with ichthyosiform or collodion skin abnormalities or with nonimmune hydrops fetalis. The cardiovascular form is characterized by calcification of the aortic and mitral valves, mild splenomegaly, corneal opacities, and supranuclear ophthalmoplegia. Cardiopulmonary complications have been described with all the clinical subtypes, although varying in frequency and severity.</Attribute>
                <XRef ID="NBK1269" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301446</ID>
                <ID Source="BookShelf">NBK1269</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2008">
                <ID Source="PubMed">18197057</ID>
                <ID Source="pmc">3110977</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACOG, 2009">
                <ID Source="PubMed">19888064</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2011">
                <URL>http://www.acmg.net/ACMG/UploadedPDFS/PDFDocuments/Carrier-Screening-ACT-SheetAshkenazi-Jewish-Genetic-Disorders.aspx</URL>
                <CitationText>American College of Medical Genetics ACT Sheet, Carrier Screening ACT Sheet Ashkenazi Jewish Genetic Disorders</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Gaucher.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Decreased ß-glucocerebrosidase, Gaucher disease, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Gaucher-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Gaucher Disease; Decreased beta-glucocerebrosidase activity, 2022</CitationText>
              </Citation>
              <XRef ID="355" DB="Orphanet" />
              <XRef ID="C0017205" DB="MedGen" />
              <XRef ID="MONDO:0018150" DB="MONDO" />
            </Trait>
          </TraitSet>
          <TraitSet ID="9460" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="17556" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">not provided</ElementValue>
                <XRef ID="13DG0619" DB="Department Of Translational Genomics (developmental Genetics Section), King Faisal Specialist Hospital &amp; Research Centre" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">none provided</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">The term 'not provided' is registered in MedGen to support identification of submissions to ClinVar for which no condition was named when assessing the variant. 'not provided' differs from 'not specified', which is used when a variant is asserted to be benign, likely benign, or of uncertain significance for conditions that have not been specified.</Attribute>
              </AttributeSet>
              <XRef ID="C3661900" DB="MedGen" />
            </Trait>
          </TraitSet>
          <TraitSet ID="1938" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="1243" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Lewy body dementia</ElementValue>
                <XRef ID="Lewy+body+dementia/4215" DB="Genetic Alliance" />
                <XRef ID="MONDO:0007488" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Diffuse Lewy body disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Autosomal dominant diffuse Lewy body disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Lewy Body Disease</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">DLB</ElementValue>
                <XRef Type="MIM" ID="127750" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="3243" />
                <XRef ID="3243" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="practice guideline" Abbrev="NICE, 2023">
                <URL>https://www.nice.org.uk/guidance/cg148</URL>
                <CitationText>UK NICE Clinical guideline (CG148), Urinary incontinence in neurological disease: assessment and management, 2023</CitationText>
              </Citation>
              <XRef ID="C0752347" DB="MedGen" />
              <XRef ID="MONDO:0007488" DB="MONDO" />
              <XRef Type="MIM" ID="127750" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="2291923" SubmissionDate="2019-09-27" DateLastUpdated="2020-02-29" DateCreated="2020-02-29">
        <ClinVarSubmissionID localKey="NC_000001.10:g.155209760_155209762delGTA|OMIM:230800;230900;231000;231005" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001162867" DateUpdated="2020-02-29" DateCreated="2020-02-29" Type="SCV" Version="1" SubmitterName="Baylor Genetics" OrgID="1006" OrganizationCategory="laboratory" OrgAbbreviation="BCM: BMGL" />
        <RecordStatus>current</RecordStatus>
        <Classification>
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GBA" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000001.10:g.155209760_155209762delGTA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="230800" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="230900" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="231000" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="231005" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>BG_GA_2018_SNVs_INDELS</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="3950001" SubmissionDate="2021-11-04" DateLastUpdated="2021-11-06" DateCreated="2021-11-06">
        <ClinVarSubmissionID localKey="NM_001005741.2:c.222_224del|MedGen:C0017205" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002011813" DateUpdated="2021-11-06" DateCreated="2021-11-06" Type="SCV" Version="1" SubmitterName="GeneID Lab - Advanced Molecular Diagnostics" OrgID="506582" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2019-01-08">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">10796875</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">19394250</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">16293621</ID>
          </Citation>
          <Comment>This variant results in an in-frame deletion, described as p.Thr75del. This finding has been described among non-Jewish patients with type 1 Gaucher disease (PMID: 10796875) and in affected patients from black South Africans population (PMID: 19394250). Aditionally experimental evidence suggest that the function of the protein harboring this substitution is impaired (PMID: 16293621). Based on these findings and the limited literature regarding this substitution we consider it as a "Pathogenic variant”.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Ethnicity>African American</Ethnicity>
              <GeographicOrigin>United States</GeographicOrigin>
              <Species TaxonomyId="9606">human</Species>
              <Age Type="minimum" age_unit="years">20</Age>
              <Age Type="maximum" age_unit="years">29</Age>
              <AffectedStatus>no</AffectedStatus>
              <Gender>female</Gender>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="1" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GBA" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_001005741.2:c.222_224del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0017205" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB10618060</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="4084942" SubmissionDate="2022-02-09" DateLastUpdated="2022-04-23" DateCreated="2022-04-23">
        <ClinVarSubmissionID localKey="NM_000157.4:c.222_224del|Gaucher disease" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002086484" DateUpdated="2022-04-23" DateCreated="2022-04-23" Type="SCV" Version="1" SubmitterName="Natera, Inc." OrgID="500034" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2020-10-26">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000157.4:c.222_224del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Gaucher disease</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB10993736</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="4933138" SubmissionDate="2022-05-21" DateLastUpdated="2022-05-28" DateCreated="2022-05-28">
        <ClinVarSubmissionID localKey="NC_000001.11:g.155239969_155239971delGTA|OMIM:127750" submittedAssembly="GRCh38" />
        <ClinVarAccession Accession="SCV002516450" DateUpdated="2022-05-28" DateCreated="2022-05-28" Type="SCV" Version="1" SubmitterName="Mendelics" OrgID="500035" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-05-04">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Mendelics Assertion Criteria 2019</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/fxi2k7be/mendelics_assertion_criteria_2019.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GBA" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000001.11:g.155239969_155239971delGTA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="127750" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>MENDELICS_CLINVAR_033</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="5429751" SubmissionDate="2022-12-13" DateLastUpdated="2022-12-31" DateCreated="2022-12-31">
        <ClinVarSubmissionID localKey="NM_001005741.3:c.222_224del|OMIM:127750;168600;230800;230900;231000;231005;608013" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002779667" DateUpdated="2022-12-31" DateCreated="2022-12-31" Type="SCV" Version="1" SubmitterName="Fulgent Genetics, Fulgent Genetics" OrgID="500105" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-04-12">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_001005741.3:c.222_224del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="TraitChoice">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="127750" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="168600" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="230800" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="230900" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="231000" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="231005" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="608013" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12390657</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7081460" SubmissionDate="2023-02-06" DateLastUpdated="2023-11-11" DateCreated="2023-02-13">
        <ClinVarSubmissionID localKey="NM_001005741.2:c.222_224delTAC|MedGen:C0017205" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV003800841" DateUpdated="2023-11-11" DateCreated="2023-02-13" Type="SCV" Version="2" SubmitterName="Women's Health and Genetics/Laboratory Corporation of America, LabCorp" OrgID="500026" OrganizationCategory="laboratory" OrgAbbreviation="WHG-LC" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-01-16">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">16293621</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">10796875</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">19394250</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">15352589</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">26792850</ID>
          </Citation>
          <Comment>Variant summary: GBA c.222_224delTAC (p.Thr75del) results in an in-frame deletion that is predicted to remove one amino acid from the encoded protein. The variant allele was found at a frequency of 5.2e-05 in 251342 control chromosomes. This frequency is not significantly higher than expected for a pathogenic variant in GBA causing Gaucher Disease (5.2e-05 vs 0.005), allowing no conclusion about variant significance. c.222_224delTAC has been reported in the literature in multiple individuals affected with Gaucher Disease (e.g., Koprivica_2000, Heitner_2004, Arndt_2009). These data indicate that the variant is very likely to be associated with disease. Several publications report experimental evidence evaluating an impact on protein function, suggesting the variant reduces enzymatic activity (e.g., Liou_2006, Arndt_2009). The most pronounced variant effect results in 35% of normal catalytic activity (Liou_2006), and in some compound heterozygous patient leukocytes, enzymatic activity was reported to range from 0% to 50% of normal activity (Arndt_2009). Seven ClinVar submitters (evaluation after 2014) have cited the variant, and all laboratories classified the variant as pathogenic (n=6) or likely pathogenic (n=1). Based on the evidence outlined above, the variant was classified as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">LabCorp Variant Classification Summary - May 2015</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/api/2.0/files/rtxspsnt/labcorp_variant_classification_method_-_may_2015.pdf/?format=attachment</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GBA1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_001005741.2:c.222_224delTAC</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0017205" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12766635</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="3971836" SubmissionDate="2021-12-15" DateLastUpdated="2023-03-04" DateCreated="2021-11-29">
        <ClinVarSubmissionID localKey="GDXSV:217145" localKeyIsSubmitted="1" />
        <ClinVarAccession Accession="SCV002028208" DateUpdated="2023-03-04" DateCreated="2021-11-29" Type="SCV" Version="3" SubmitterName="GeneDx" OrgID="26957" OrganizationCategory="laboratory" OrgAbbreviation="GDX" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-12-02">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>Published functional studies demonstrate a damaging effect with this variant resulting in deceased enzyme activity (Liou et al., 2006); In-frame deletion of one amino acid in a non-repeat region; Also known as p.T36del using alternate nomenclature; This variant is associated with the following publications: (PMID: 10796875, 30548430, 29625052, 32035846, 19394250, 16293621)</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">GeneDx Variant Classification Process June 2021</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/fc81e176/genedx_variant_classification_process_june_2021.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GBA" />
          </GeneList>
          <VariantType>Deletion</VariantType>
          <OtherNameList>
            <Name Type="SubmitterVariantId">GDX:748162</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_001005741.2:c.222_224del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Not Provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>GeneDX_Clinvar_Submission_72_20211124054205</SubmissionName>
          <SubmissionName>GeneDX_Clinvar_Submission_75_20211215054204</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7901160" SubmissionDate="2024-01-05" DateLastUpdated="2024-01-26" DateCreated="2024-01-26">
        <ClinVarSubmissionID localKey="1513419|Not provided" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004228232" DateUpdated="2024-01-26" DateCreated="2024-01-26" Type="SCV" Version="1" SubmitterName="Mayo Clinic Laboratories, Mayo Clinic" OrgID="500068" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-02-09">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">10796875</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">12587096</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">16293621</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">17059888</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">19394250</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">21704274</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">30169122</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">30548430</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">32035846</ID>
          </Citation>
          <Comment>PP4, PM2, PM3_strong, PM4, PS3_moderate, PS4_moderate</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="1" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GBA1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <GeneLocation>NM_000157.4:exon 3</GeneLocation>
          </Location>
          <OtherNameList>
            <Name>p.Thr75del</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000157.4:c.222_224del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Not provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB14137495</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="3963497" SubmissionDate="2024-01-26" DateLastUpdated="2024-02-04" DateCreated="2021-11-29">
        <ClinVarSubmissionID localKey="93f51968898325fddfc9356b2fdcae5b2e3b6cad4ad8f624a51725a9d4d0b0b4|not provided" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002018403" DateUpdated="2024-02-04" DateCreated="2021-11-29" Type="SCV" Version="3" SubmitterName="Revvity Omics, Revvity" OrgID="167595" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-07-25">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Likely pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_001005741.3:c.222_224del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">not provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB10694847</SubmissionName>
          <SubmissionName>SUB12926214</SubmissionName>
          <SubmissionName>SUB14173319</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1829338" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-14" DateCreated="2019-08-14">
        <ClinVarSubmissionID localKey="4327360|MedGen:CN517202" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000935509" DateUpdated="2024-02-14" DateCreated="2019-08-14" Type="SCV" Version="5" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2024-01-08">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">10796875</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">19394250</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">16293621</ID>
          </Citation>
          <Comment>This variant, c.222_224del, results in the deletion of 1 amino acid(s) of the GBA protein (p.Thr75del), but otherwise preserves the integrity of the reading frame. This variant is present in population databases (rs761621516, gnomAD 0.04%). This variant has been observed in individuals with Gaucher disease (PMID: 10796875, 19394250). This variant is also known as T36del. ClinVar contains an entry for this variant (Variation ID: 642539). Algorithms developed to predict the effect of variants on protein structure and function are not available or were not evaluated for this variant. Experimental studies have shown that this variant affects GBA function (PMID: 16293621). For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GBA1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000001.10:g.155209760_155209762del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="CN517202" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11431369</SubmissionName>
          <SubmissionName>SUB14200283</SubmissionName>
          <SubmissionName>SUB8755776</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="5429751" TraitType="Disease" MappingType="XRef" MappingValue="127750" MappingRef="OMIM">
        <MedGen CUI="C0752347" Name="Lewy body dementia" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1829338" TraitType="Disease" MappingType="XRef" MappingValue="CN517202" MappingRef="MedGen">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2291923" TraitType="Disease" MappingType="XRef" MappingValue="231005" MappingRef="OMIM">
        <MedGen CUI="C1856476" Name="Gaucher disease-ophthalmoplegia-cardiovascular calcification syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7081460" TraitType="Disease" MappingType="XRef" MappingValue="C0017205" MappingRef="MedGen">
        <MedGen CUI="C0017205" Name="Gaucher disease" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5429751" TraitType="Disease" MappingType="XRef" MappingValue="168600" MappingRef="OMIM">
        <MedGen CUI="C3160718" Name="Parkinson disease, late-onset" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5429751" TraitType="Disease" MappingType="XRef" MappingValue="231005" MappingRef="OMIM">
        <MedGen CUI="C1856476" Name="Gaucher disease-ophthalmoplegia-cardiovascular calcification syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4933138" TraitType="Disease" MappingType="XRef" MappingValue="127750" MappingRef="OMIM">
        <MedGen CUI="C0752347" Name="Lewy body dementia" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3963497" TraitType="Disease" MappingType="Name" MappingValue="not provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2291923" TraitType="Disease" MappingType="XRef" MappingValue="231000" MappingRef="OMIM">
        <MedGen CUI="C0268251" Name="Gaucher disease type III" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5429751" TraitType="Disease" MappingType="XRef" MappingValue="608013" MappingRef="OMIM">
        <MedGen CUI="C1842704" Name="Gaucher disease perinatal lethal" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5429751" TraitType="Disease" MappingType="XRef" MappingValue="230800" MappingRef="OMIM">
        <MedGen CUI="C1961835" Name="Gaucher disease type I" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5429751" TraitType="Disease" MappingType="XRef" MappingValue="231000" MappingRef="OMIM">
        <MedGen CUI="C0268251" Name="Gaucher disease type III" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4084942" TraitType="Disease" MappingType="Name" MappingValue="Gaucher disease" MappingRef="Preferred">
        <MedGen CUI="C0017205" Name="Gaucher disease" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2291923" TraitType="Disease" MappingType="XRef" MappingValue="230800" MappingRef="OMIM">
        <MedGen CUI="C1961835" Name="Gaucher disease type I" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7901160" TraitType="Disease" MappingType="Name" MappingValue="Not provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5429751" TraitType="Disease" MappingType="XRef" MappingValue="230900" MappingRef="OMIM">
        <MedGen CUI="C0268250" Name="Gaucher disease type II" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2291923" TraitType="Disease" MappingType="XRef" MappingValue="230900" MappingRef="OMIM">
        <MedGen CUI="C0268250" Name="Gaucher disease type II" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3971836" TraitType="Disease" MappingType="Name" MappingValue="Not Provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3950001" TraitType="Disease" MappingType="XRef" MappingValue="C0017205" MappingRef="MedGen">
        <MedGen CUI="C0017205" Name="Gaucher disease" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

